C-erbB-2, p53, and nm23 gene product expression in breast cancer in young women: Immunohistochemical analysis and clinicopathologic correlation

Human Pathology

Volumn 29, Issue 4, 1998, Pages 323-329

  Bertheau, Philippe ^a   Steinberg, Seth M ^b   Merino, Maria J ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b NONE

Author keywords

Breast cancer; C erbB 2; Immunohistochemistry; Nm23; P53; Young woman

Indexed keywords

ESTROGEN RECEPTOR; GENE PRODUCT; ONCOPROTEIN; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; AGE; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER RECURRENCE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; ONCOGENE C ERB; PROGNOSIS; SURVIVAL RATE;

EID: 0031778195     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(98)90111-3     Document Type: Article

References (36)

1. Dawkins HJ, Robbins PD, Smith KL, et al: What's new in breast cancer? Molecular perspectives of cancer development and the role of the oncogene c-erbB-2 in prognosis and disease. Pathol Res Pract 189:1233-1252, 1993
2. Barbareschi M: Prognostic value of the immunohistochemical expression of p53 in breast carcinomas: A review of the literature involving over 9,000 patients. Appl Immunohistochem 4:106-116, 1996
3. MacGrogan G, Bonichon F, de Mascarel I, et al: Prognostic value of p53 in breast invasive ductal carcinoma: An immunohistochemical study on 942 cases. Breast Cancer Res Treat 36:71-81, 1995
4. Barnes DM, Dublin EA, Fisher CJ, et al: Immunohistochemical detection of p53 protein in mammary carcinoma: An important new independent indicator of prognosis? HUM PATHOL 24:469-476, 1993
5. Royds JA, Stephenson TJ, Rees RC, et al: Nm23 protein expression in ductal in situ and invasive human breast carcinoma. J Natl Cancer Inst 85:727-731, 1993
6. Barnes R, Masood S, Barker E, et al: Low nm23 protein expression in infiltrating ductal breast carcinomas correlates with reduced patients survival. Am J Pathol 139:245-250, 1991
7. Bevilacqua G, Sobel ME, Liotta LA, et al: Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential. Cancer Res 49:5185-5190, 1989
8. Rosengard AM, Krutzsch HC, Shearn A, et al: Reduced Nm23/Awd protein in tumour metastasis and aberrant Drosophila development. Nature 342:177-180, 1989
9. Mehta CR, Patel NR: A network algorithm for performing Fisher's exact test in r × c contingency tables. J Am Stat Assoc 78:427-434, 1983
10. Kaplan E, Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
11. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chem Rep 50:163-170, 1966
12. Cox D: Regression models and lifetables. J R Stat Soc (B) 34:187-202, 1972
13. Quenel N, Wafflart J, Bonichon F, et al: The prognostic value of c-erbB-2 in primary breast carcinomas: A study on 942 cases. Breast Cancer Res Treat 35:283-291, 1995
14. Rosen PP, Lesser ML, Arroyo CD, et al: Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma: A study of epidemiologic risk factors, histologic features, and prognosis. Cancer 75:1320-1326, 1995
15. Blanchi S, Paglierani M, Zampi G, et al: Prognostic significance of c-erbB-2 expression in node negative breast cancer. Br J Cancer 67:625-629, 1993
16. Omalley FP, Saad Z, Kerkvliet N, et al: The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb b-2 in lymph node-negative breast cancer. HUM PATHOL 27:955-963, 1996
17. Macgrogan G, Mauriac L, Durand M, et al: Primary chemotherapy in breast invasive carcinoma: Predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbb-2, mib1, ps2 and gst-pi. Br J Cancer 74:1458-1465, 1996
18. Gullick WJ, Love SB, Wright C, et al: c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63:434-438, 1991
19. Martinazzi M, Crivelli F, Zampatti C, et al: Relationship between p53 expression and other prognostic factors in human breast carcinoma: An immunohistochemical study. Am J Clin Pathol 100:213-217, 1993
20. Barbareschi M, Leonardi E, Mauri FA, et al: p53 and c-erbB-2 protein expression in breast carcinomas: An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Am J Clin Pathol 98:408-418, 1992
21. Thor AD, Moore DH, Edgerton SM, et al: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845-855, 1992
22. Lipponen P, Ji H, Aaltomaa S, et al: p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int J Cancer 55:51-56, 1993
23. Barbareschi M, Caffo O, Veronese S, et al: Bcl-2 and p53 expression in node-negative breast carcinoma: A study with long-term follow-up. HUM PATHOL 27:1149-1155, 1996
24. Haerslev T, Jacobsen GK; An immunohistochemical study of p53 with correlations to histopathological parameters, c-erbB-2, proliferating cell nuclear antigen, and prognosis. HUM PATHOL 26:295-301, 1995
25. Charpin C, De VB, Andrac L, et al: p53 quantitative immunocytochemical analysis in breast carcinomas. HUM PATHOL 26:159-166, 1995
26. Trudel M, Mulligan L, Cavenee W, et al: Retinoblastoma and p53 gene product expression in breast carcinoma: Immunohistochemical analysis and clinicopathologic correlation. HUM PATHOL 23:1388-1394, 1992
27. Home GM, Anderson JJ, Tiniakos DG, et al: p53 protein as a prognostic indicator in breast carcinoma: A comparison of four antibodies for immunohistochemistry. Br J Cancer 73:29-35, 1996
28. Stenmark AM, Stal O, Olsen K, et al: p53 as a prognosticfactor in stage I breast cancer. South-East Sweden Breast Cancer Group. Br J Cancer 72:715-719, 1995
29. Takeda O, Handa M, Uehara T, et al: An increased nm23h1 copy number may be a poor prognostic factor independent of loh on 1p in neuroblastomas. Br J Cancer 74:1620-1626, 1996
30. Zeng ZS, Hsu S, Zhang ZF, et al: High level of Nm23-H1 gene expression is associated with local colorectal cancer progression not with metastases. Br J Cancer 70:1025-1030, 1994
31. Bertheau P, De La Rosa A, Steeg PS, et al: NM23 protein in neoplastic and nonneoplastic thyroid tissues. Am J Pathol 145:26-32, 1994
32. Chung M, Chang HR, Bland KI, et al: Younger women with breast carcinoma have a poorer prognosis than older women. Cancer 77:97-103, 1996
33. Bonnier P, Romain S, Charpin C, et al: Age as a prognostic factor in breast cancer: Relationship to pathologic and biologic features. Int J Cancer 62:138-144, 1995
34. Winchester DP, Osteen RT, Menck HR: The national cancer data base report on breast carcinoma characteristics and outcome in relation to age. Cancer 78:1838-1843, 1996
35. Von Rosen A, Fallenius A, Sundelin B, et al: Nuclear DNA content in mammary carcinomas in women aged 35 or younger. Am J Clin Oncol 9:382-386, 1986
36. Xing WR, Gilchrist KW, Harris CP, et al: FISH detection of HER-2/neu oncogene amplification in early onset breast cancer. Breast Cancer Res Treat 39:203-212, 1996